Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Total Non-Current Liabilities (2020 - 2026)

Cardiol Therapeutics filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $4.6 million for Q4 2022.

  • On a quarterly basis, Total Non-Current Liabilities fell 21.48% to $4.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $4.6 million, a 21.48% decrease, with the full-year FY2022 number at $4.6 million, down 21.48% from a year prior.
  • Total Non-Current Liabilities hit $4.6 million in Q4 2022 for Cardiol Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $5.9 million in Q4 2021 to a low of -$1.7 million in Q2 2021.
  • Median Total Non-Current Liabilities over the past 3 years was $4.4 million (2022), compared with a mean of $2.5 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 519.88% in 2021 and later decreased 21.48% in 2022.
  • Cardiol Therapeutics' Total Non-Current Liabilities stood at -$1.4 million in 2020, then skyrocketed by 519.88% to $5.9 million in 2021, then fell by 21.48% to $4.6 million in 2022.
  • The last three reported values for Total Non-Current Liabilities were $4.6 million (Q4 2022), $4.7 million (Q3 2022), and $4.6 million (Q2 2022) per Business Quant data.